Patients responding to one form of hormonal treatment had a greater likelihood of responding to subsequent hormonal manipulations. Additive hormonal therapy may provide effective palliation in males with advanced breast...
HER2-directed therapy: current treatment options for HER2-positive breast cancer Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imagin... S Ahmed,A Sami,J Xiang - 《Breast Cancer》 被引量: 74...
V Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L Setting By University of Colorado Cancer Center FEATURING Virginia Borges April 13, 2023 Comments 0 Login to view comments. Click here to Login Featured Video 11:11 Lilly Medical Affairs Supporting Patients With Brea...
Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies.
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
Options available to treat patients with HER2-positive metastatic breast cancer following frontline therapy with T-DM1.
[1] Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023 Sep 8;9(1):74. [2] Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistan...
Buchholz SM, Nause N, König U, Reinecke J, Steuber B, Ammer-Herrmenau C, Reuter-Jessen K, Bohnenberger H, Biggemann L, Braulke F, Neesse A, Ellenrieder V, Ströbel P, Adler M, König A. Time to Deliver on Promises: The Role of ERBB2 Alterations as Treatment Options for Co...
[1] Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023 Sep 8;9(1):74. [2] Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistan...
HER2 positive and HER2 low patients, who may benefit from HER2-targeted therapies and HER2 antibody-drug conjugates. The ability to monitor HER2 status over time from repeat blood samples may provide valuable data for assessing treatment options. The combination of ANGLE’s Parsortix system f...